Delaware Funds by Macquarie > Delaware Group Equity Funds IV
Delaware Healthcare Fund
$764.40M
Avg Monthly Net Assets
$785.71M
Total Assets
$1.55M
Total Liabilities
$784.16M
Net Assets
Delaware Healthcare Fund is a Mutual Fund in Delaware Group Equity Funds IV
from Delaware Funds by Macquarie,
based in Pennsylvania,
United States of America.
The fund has four share classes
and monthly net assets of $764.40M.
On August 27th, 2024 it reported 106 holdings, the largest
being Eli Lilly & Co (13.9%), Regeneron Pharmaceuticals Inc (6.8%) and Amgen Inc (6.4%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Class A | C000052257 | DLHAX | |
| Class C | C000052258 | DLHCX | |
| Class R | C000052259 | DLRHX | |
| Institutional Class | C000052260 | DLHIX |
Holdings
From latest NPORT-P, filed August 27th, 2024 for period ending June 28th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| AbbVie Inc | Long | Equity-common | US | $22M | 130K | 2.84 |
| ACADIA Pharmaceuticals Inc | Long | Equity-common | US | $2M | 93K | 0.19 |
| Alkermes PLC | Long | Equity-common | IE | $7M | 300K | 0.92 |
| Allogene Therapeutics Inc | Long | Equity-common | US | $342K | 147K | 0.04 |
| Alnylam Pharmaceuticals Inc | Long | Equity-common | US | $7M | 30K | 0.93 |
| Altimmune Inc | Long | Equity-common | US | $665K | 100K | 0.08 |
| Amarin Corp PLC | Long | Equity-common | IE | $131K | 190K | 0.02 |
| AMBIT BIOSCIENCES CORP CVR | Long | Equity-common | US | $0 | 77K | – |
| Amgen Inc | Long | Equity-common | US | $50M | 160K | 6.38 |
| AnaptysBio Inc | Long | Equity-common | US | $2M | 94K | 0.30 |
| Arcus Biosciences Inc | Long | Equity-common | US | $6M | 379K | 0.74 |
| AstraZeneca PLC | Long | Equity-common | GB | $20M | 131K | 2.61 |
| Atea Pharmaceuticals Inc | Long | Equity-common | US | $232K | 70K | 0.03 |
| Biogen Inc | Long | Equity-common | US | $6M | 28K | 0.83 |
| BioMarin Pharmaceutical Inc | Long | Equity-common | US | $9M | 110K | 1.15 |
| BioNTech SE | Long | Equity-common | DE | $1M | 18K | 0.18 |
| BlackRock Liquidity FedFund | Long | Short-term investment vehicle | US | $4M | 4M | 0.53 |
| Boston Scientific Corp | Long | Equity-common | US | $29M | 380K | 3.73 |
| Cellectis SA | Long | Equity-common | FR | $424K | 227K | 0.05 |
| Chugai Pharmaceutical Co Ltd | Long | Equity-common | JP | $21M | 580K | 2.63 |
| Cia de Minas Buenaventura SAA | Long | Equity-common | PE | $1M | 66K | 0.14 |
| Cogent Biosciences Inc | Long | Equity-common | US | $2M | 230K | 0.25 |
| Coherus Biosciences Inc | Long | Equity-common | US | $2M | 900K | 0.20 |
| Compugen Ltd | Long | Equity-common | IL | $2M | 1M | 0.22 |
| Contra Surface Oncolog | Long | Equity-common | US | $27K | 350K | 0.00 |
| CVS Health Corp | Long | Equity-common | US | $6M | 100K | 0.75 |
| Cytokinetics Inc | Long | Equity-common | US | $2M | 30K | 0.21 |
| Day One Biopharmaceuticals Inc | Long | Equity-common | US | $2M | 110K | 0.19 |
| Dynavax Technologies Corp | Long | Equity-common | US | $6M | 570K | 0.82 |
| Elevance Health Inc | Long | Equity-common | US | $34M | 63K | 4.35 |
| Eli Lilly & Co | Long | Equity-common | US | $109M | 120K | 13.86 |
| Euroapi SA | Long | Equity-common | FR | $24K | 9K | 0.00 |
| Exact Sciences Corp | Long | Equity-common | US | $4M | 91K | 0.49 |
| Federal Home Loan Mortgage Corp (Freddie Mac) | Long | Equity-common | US | $1M | 1M | 0.18 |
| Federal National Mortgage Association (Fannie Mae) | Long | Equity-common | US | $2M | 1M | 0.24 |
| Fidelity Government Portfolio | Long | Short-term investment vehicle | US | $4M | 4M | 0.53 |
| Fortress Biotech Inc | Long | Equity-common | US | $11K | 7K | 0.00 |
| Galmed Pharmaceuticals Ltd | Long | Equity-common | IL | $6K | 20K | 0.00 |
| Gilead Sciences Inc | Long | Equity-common | US | $14M | 210K | 1.84 |
| Goldman Sachs Financial Square Government Fund | Long | Short-term investment vehicle | US | $4M | 4M | 0.53 |
| GRAIL Inc | Long | Equity-common | US | $256K | 17K | 0.03 |
| Halozyme Therapeutics Inc | Long | Equity-common | US | $12M | 220K | 1.47 |
| Illumina Inc | Long | Equity-common | US | $10M | 100K | 1.33 |
| Immunovant Inc | Long | Equity-common | US | $3M | 122K | 0.41 |
| Incyte Corp | Long | Equity-common | US | $5M | 80K | 0.62 |
| InnoCare Pharma Ltd | Long | Equity-common | CN | $10K | 17K | 0.00 |
| Intellia Therapeutics Inc | Long | Equity-common | US | $448K | 20K | 0.06 |
| Intra-Cellular Therapies Inc | Long | Equity-common | US | $6M | 90K | 0.79 |
| Janux Therapeutics Inc | Long | Equity-common | US | $3M | 77K | 0.41 |
| Karyopharm Therapeutics Inc | Long | Equity-common | US | $434K | 500K | 0.06 |
| Kenvue Inc | Long | Equity-common | US | $3M | 187K | 0.43 |
| LANDOS BIOPHARMA INC | Long | Equity-common | US | $37K | 15K | 0.00 |
| MacroGenics Inc | Long | Equity-common | US | $2M | 420K | 0.23 |
| Madrigal Pharmaceuticals Inc | Long | Equity-common | US | $8M | 29K | 1.02 |
| MEI Pharma Inc | Long | Equity-common | US | $87K | 30K | 0.01 |
| Merck & Co Inc | Long | Equity-common | US | $37M | 295K | 4.66 |
| Mersana Therapeutics Inc | Long | Equity-common | US | $302K | 150K | 0.04 |
| MIRATI THERAPEUTICS INC | Long | Equity-common | US | $42K | 60K | 0.01 |
| Moderna Inc | Long | Equity-common | US | $1M | 10K | 0.15 |
| MSILF Government Portfolio | Long | Short-term investment vehicle | US | $4M | 4M | 0.53 |
| Mural Oncology PLC | Long | Equity-common | IE | $94K | 30K | 0.01 |
| Mustang Bio Inc | Long | Equity-common | US | $4K | 8K | 0.00 |
| Myriad Genetics Inc | Long | Equity-common | US | $1M | 50K | 0.16 |
| Nektar Therapeutics | Long | Equity-common | US | $318K | 256K | 0.04 |
| Neurocrine Biosciences Inc | Long | Equity-common | US | $11M | 80K | 1.40 |
| NextCure Inc | Long | Equity-common | US | $239K | 150K | 0.03 |
| Organon & Co | Long | Equity-common | US | $611K | 30K | 0.08 |
| Perrigo Co PLC | Long | Equity-common | IE | $6M | 230K | 0.75 |
| Pfizer Inc | Long | Equity-common | US | $32M | 1M | 4.09 |
| ProQR Therapeutics NV | Long | Equity-common | NL | $1M | 620K | 0.13 |
| Proteostasis Theapeutics | Long | Equity-common | US | $0 | 750K | – |
| Puma Biotechnology Inc | Long | Equity-common | US | $200K | 61K | 0.03 |
| Quest Diagnostics Inc | Long | Equity-common | US | $4M | 30K | 0.52 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $54M | 51K | 6.84 |
| REGENXBIO Inc | Long | Equity-common | US | $2M | 149K | 0.22 |
| Rigel Pharmaceuticals Inc | Long | Equity-common | US | $1M | 160K | 0.17 |
| Roche Holding AG | Long | Equity-common | CH | $22M | 80K | 2.83 |
| Rocket Pharmaceuticals Inc | Long | Equity-common | US | $1M | 58K | 0.16 |
| Roivant Sciences Ltd | Long | Equity-common | US | $4M | 338K | 0.46 |
| Sangamo Therapeutics Inc | Long | Equity-common | US | $143K | 400K | 0.02 |
| Sanofi SA | Long | Equity-common | FR | $16M | 165K | 2.03 |
| Sarepta Therapeutics Inc | Long | Equity-common | US | $2M | 11K | 0.22 |
| SIO GENE THERAPIES INC | Long | Equity-common | US | $0 | 64K | – |
| Sohu.com Ltd | Long | Equity-common | CN | $5M | 391K | 0.69 |
| Structure Therapeutics Inc | Long | Equity-common | US | $2M | 58K | 0.29 |
| Stryker Corp | Long | Equity-common | US | $5M | 15K | 0.65 |
| Syndax Pharmaceuticals Inc | Long | Equity-common | US | $4M | 180K | 0.47 |
| Tarsus Pharmaceuticals Inc | Long | Equity-common | US | $4M | 150K | 0.52 |
| Theravance Biopharma Inc | Long | Equity-common | KY | $2M | 209K | 0.23 |
| Topcon Corp | Long | Equity-common | JP | $188K | 17K | 0.02 |
| UCB SA | Long | Equity-common | BE | $17M | 112K | 2.12 |
| Ultragenyx Pharmaceutical Inc | Long | Equity-common | US | $3M | 70K | 0.37 |
| uniQure NV | Long | Equity-common | NL | $3M | 706K | 0.40 |
| United Therapeutics Corp | Long | Equity-common | US | $4M | 14K | 0.57 |
| UnitedHealth Group Inc | Long | Equity-common | US | $39M | 76K | 4.94 |
| Ventyx Biosciences Inc | Long | Equity-common | US | $993K | 430K | 0.13 |
| Vertex Pharmaceuticals Inc | Long | Equity-common | US | $12M | 25K | 1.49 |
| Viatris Inc | Long | Equity-common | US | $12M | 1M | 1.59 |
| Viking Therapeutics Inc | Long | Equity-common | US | $17M | 330K | 2.23 |
| Viridian Therapeutics Inc | Long | Equity-common | US | $382K | 29K | 0.05 |
| Voyager Therapeutics Inc | Long | Equity-common | US | $45K | 6K | 0.01 |
| WaVe Life Sciences Ltd | Long | Equity-common | US | $409K | 82K | 0.05 |
| Xencor Inc | Long | Equity-common | US | $4M | 200K | 0.48 |
| XOMA Corp | Long | Equity-common | US | $82K | 3K | 0.01 |
| Zimmer Biomet Holdings Inc | Long | Equity-common | US | $9M | 80K | 1.11 |
| Zimvie Inc | Long | Equity-common | US | $146K | 8K | 0.02 |
Address
Delaware Group Equity Funds IV
100 Independence
610 Market Street
Philadelphia
Pennsylvania
19106-2354
United States of America
Websites
Directors
Ann D. Borowiec
Christianna Wood
Frances A. Sevilla-Sacasa
H. Jeffrey Dobbs
Jerome D. Abernathy
John A. Fry
Joseph Harroz, Jr.
Joseph W. Chow
Sandra A.J. Lawrence
Shawn K. Lytle
Thomas K. Whitford
Transfer Agents
BNY Mellon Investment Servicing (US) Inc.
Delaware Investments Fund Services Company
Pricing Services
Bloomberg L.P.
ICE Data Pricing & Reference Data, LLC
LSEG Data & Analytics
S&P Global Inc.
Custodians
Banque Nationale de Belgique SA/NV
Citibanamex, Mexico City
Euroclear Bank
Euroclear Belgium
Euroclear France
Mizuho Bank, Ltd.
Skandinaviska Enskilda Banken AB, Copenhagen Branch
Skandinaviska Enskilda Banken AB, Stockholm
TMX GROUP LIMITED
The Bank of New York Mellon
The Bank of New York Mellon (United Kingdom)
The Bank of New York Mellon SA/NV, Asset Servicing, Niederlassung Frankfurt am Main
The Bank of New York Mellon, SA/NV (Italy)
The Bank of New York Mellon, SA/NV (Netherlands)
The Hongkong and Shanghai Banking Corporation (Hong Kong)
UBS SWITZERLAND AG (T2S)
UBS Switzerland AG
Shareholder Servicing Agents
Delaware Investments Fund Services Company
Admins
BNY Mellon Investment Servicing (US) Inc.
Brokers
GOLDMAN SACHS & CO. LLC
JEFFERIES LLC
UBS Securities LLC
MORGAN STANLEY & CO. LLC
BNP Paribas Securities Corp.
BARCLAYS CAPITAL, INC.
RBC CAPITAL MARKETS, LLC
EVERCORE GROUP LLC
VIRTU AMERICAS LLC
BOFA SECURITIES, INC.